Our
Team

Our world-class, multidisciplinary team of psychedelic, drug development, commercialisation and digital experts are united by their determination to help people living with neuropsychiatric disorders.

Our
Executive
Team
Our
Board
of
Directors
Rob Hershberg, M.D., Ph.D.
Board member
Rob Hershberg, M.D., Ph.D.
Board member
Rob Hershberg, M.D., Ph.D., is Co-Founder President, Chief Executive Officer and chairman of the board of directors of HilleVax. Rob is also a Venture Partner with Frazier Healthcare Partners and has been working with Frazier and its portfolio companies as an Entrepreneur-in-Residence, Senior Advisor, and executive for 14 years. He was formerly President and Chief Executive Officer of VentiRx Pharmaceuticals, a Frazier-founded company developing a small molecule therapeutic to activate the immune system against solid tumors which he co-founded while an entrepreneur-in-residence at Frazier. Rob led the company through its transformational partnership with Celgene. He joined Celgene in 2014 to lead their efforts in Immuno-Oncology, was promoted to Executive Vice President and Chief Scientific Officer in 2016 and was subsequently Executive Vice President and Head of Business Development & Global Alliances until the acquisition of Celgene by Bristol-Myers Squibb in 2019. Prior to VentiRx, Rob served as Senior Vice President and Chief Medical Officer of Dendreon Corporation and led clinical development of Provenge, which was approved for metastatic prostate cancer. Before Dendreon, he was Vice President of Medical Genetics at Corixa, a Frazier portfolio company which was acquired by GlaxoSmithKline. Earlier, Rob was an Assistant Professor at Harvard Medical School and an Associate Physician at Brigham and Women’s Hospital in Boston. Rob completed his undergraduate and medical degrees at the University of California, Los Angeles and received his Ph.D. at the Salk Institute for Biological Studies.
Our
Investors

Dr. Robin L Carhart-Harris

Professor Matthew W Johnson PhD

Other investors include investment entities (e.g. funds and family offices) and individuals.